LC-MS/MS法测定人血浆中氯吡格雷浓度及两种片剂的生物等效性研究
x

请在关注微信后,向客服人员索取文件

篇名: LC-MS/MS法测定人血浆中氯吡格雷浓度及两种片剂的生物等效性研究
TITLE:
摘要: 目的:建立测定人血浆中氯吡格雷浓度的方法,研究两种硫酸氢氯吡格雷片剂的生物等效性。方法:60名健康男性受试者随机分为A、B、C、D四组,采用两制剂四周期重复交叉设计,分别空腹(A、B组)和餐后(C、D组)口服受试制剂及参比制剂各75 mg,采用液相色谱-串联质谱(LC-MS/MS)法测定人血浆中氯吡格雷的浓度。以地西泮为内标,色谱柱为Ultimate XB-C18,流动相为乙腈-0.05%甲酸溶液(84 ∶ 16,V/V),以多反应监测方式进行正离子扫描,用于定量分析的离子对分别为m/z 322.00→212.00(氯吡格雷)、m/z 285.00→154.00(内标),采用DAS 3.2.8软件计算药动学参数,以双向单侧t检验、非参数检验法考察两制剂的生物等效性。结果:氯吡格雷血药浓度在20~5 000 pg/ml范围内线性关系良好。空腹口服受试制剂或参比制剂的tmax分别为(0.850±0.356)、(0.764±0.336)h,cmax分别为(1 514.550±1 120.469)、(1 506.900±1 054.008)pg/ml,t1/2分别为(4.036±3.615)、(4.056±4.193)h,AUC0-t分别为(2 721.814±2 062.832)、(2 826.051±2 526.683)pg·h/ml;餐后口服受试制剂或参比制剂的tmax分别为(1.513±0.709)、(1.558±0.743)h,cmax分别为(5 219.509±2 711.907)、(5 520.337±3 336.664)pg/ml,t1/2分别为(5.800±4.729)、(5.513±4.206)h;AUC0-t分别为(10 890.81±4 101.357)、(11 350.653±4 174.848)pg·h/ml。两种给药条件下,受试制剂AUC0-t、AUC0-∞、cmax的90%置信区间均在参比制剂相应参数的80%~125%之内,两制剂tmax间的差异均无统计学意义(P>0.05)。结论:该方法快速、灵敏,无杂质干扰。两种片剂生物等效。
ABSTRACT: OBJECTIVE: To establish a method for the determination of clopidogrel in human plasma, and to study the bioequvivalence of 2 kinds of Clopidogrel hydrogen sulfate tablets. METHODS: 60 healthy male volunteers were randomly divided into group A, B, C and D. By four cycles repeated cross-over design, they were given fasting (group A and B) and postprandial (group C and D) test or reference preparation 75 mg. The concentration of clopidogrel in human plasma was determined by LC-MS/MS. Using diazepam as internal standard, Ultimate XB-C18 column was adopted with mobile phase consisted of acetonitrile-0.05% formic acid (84 ∶ 16,V/V). Positive ion detection was conducted in MRM mode, and monitoring transition ion-pair was m/z 322.00→212.00 for clopidogrel and m/z 285.00→154.00 for internal standard. Pharmacokinetic parameters were calculated by using DAS 3.2.8 software, and two-way and unilateral t test and non-parameters test were used to investigate the bioequivalence of two preparations. RESULTS: The linear rang of clopidogrel was 20-5 000 pg/ml. The pharmacokinetic parameters of test preparation or reference preparation after fasting oral administration were as follows: tmax were(0.850±0.356) and (0.764±0.336)h; cmax were (1 514.550± 1 120.469) and (1 506.900±1 054.008)pg/ml; t1/2 were (4.036±3.615) and (4.056±4.193)h; AUC0-t were (2 721.814±2 062.832) and (2 826.051±2 526.683) pg·h/ml. Those of test preparation or reference preparation after postprandial oral administration were as follows: tmax were (1.513±0.709) and (1.558±0.743)h; cmax were (5 219.509±2 711.907) and (5 520.337±3 336.664) pg/ml; t1/2 were (5.800±4.729) and (5.513±4.206)h; AUC0-t were (10 890.81±4 101.357)and(11 350.653±4 174.848) pg·h/ml. Under two kinds of condition, 90%CI of AUC0-t, AUC0-∞ and cmax of test preparations were 80%-125% of corresponding parameters of reference preparations, there was no statistical significance in tmax between two preparations(P>0.05). CONCLUSIONS: The method is rapid, sensitive with no endogenous interference. Two tablets are bioequivalent.
期刊: 2016年第27卷第11期
作者: 束超,徐怀友,邵凤,赵理杰,陶春蕾
AUTHORS: SHU Chao,XU Huaiyou,SHAO Feng,ZHAO Lijie,TAO Chunlei
关键字: 硫酸氢氯吡格雷片;氯吡格雷;药动学;生物等效性;液相色谱-串联质谱法
KEYWORDS: Clopidogrel hydrogen sulphate tablet; Clopidogrel; Pharmacokinetics; Bioequivalence; LC-MS/MS
阅读数: 357 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!